Patents by Inventor Roberto PILI

Roberto PILI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • THERAPEUTIC TARGETING OF RECEPTOR TYROSINE KINASE INHIBITOR-INDUCED ANDROGEN RECEPTOR PHOSPHORYLATION IN CANCER
    Publication number: 20240165078
    Abstract: Disclosed herein are compositions and methods for treating cancer. More particularly, the present disclosure relates to compositions and methods for treating cancer including prostate cancer, renal cell carcinoma, hepatocellular carcinoma, thyroid cancer, sarcoma breast cancer, and gastrointestinal stromal tumor.
    Type: Application
    Filed: January 31, 2024
    Publication date: May 23, 2024
    Inventor: Roberto Pili
  • COMBINATION THERAPY FOR TREATING CANCER
    Publication number: 20210353632
    Abstract: The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents (such as tyrosine kinase inhibitors or VEGF/VEGFR inhibitors), particularly anticancer agents such as sunitinib, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Application
    Filed: April 28, 2021
    Publication date: November 18, 2021
    Inventors: Heike KEILHACK, Roberto PILI
  • Combination therapy for treating cancer
    Patent number: 11026949
    Abstract: The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents (such as tyrosine kinase inhibitors or VEGF/VEGFR inhibitors), particularly anticancer agents such as sunitinib, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: June 8, 2021
    Assignees: Epizyme, Inc., Health Research, Inc.
    Inventors: Heike Keilhack, Roberto Pili
  • THERAPEUTIC TARGETING OF RECEPTOR TYROSINE KINASE INHIBITOR-INDUCED ANDROGEN RECEPTOR PHOSPHORYATION IN CANCER
    Publication number: 20200345692
    Abstract: Disclosed herein are compositions and methods for treating cancer. More particularly, the present disclosure relates to compositions and methods for treating cancer including prostate cancer, renal cell carcinoma, hepatocellular carcinoma, thyroid cancer, sarcoma breast cancer, and gastrointestinal stromal tumor. The present disclosure also relates to methods for identifying subjects having drug resistant prostate cancer and drug resistant renal cell carcinoma.
    Type: Application
    Filed: January 18, 2019
    Publication date: November 5, 2020
    Inventor: Roberto Pili
  • Use of histone deacetylase inhibitors for enhancing immunotherapies
    Patent number: 10813919
    Abstract: Compositions including combinations of class I histone deacetylase (HDAC) inhibitors and programmed cell death protein 1 (PD-1) inhibitors for enhancing antitumor activity are disclosed. Further disclosed are methods of administering these compositions as immunotherapies for suppressing regulatory T cells in renal cell carcinoma.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: October 27, 2020
    Assignee: Indiana University Research and Technology Corporation
    Inventor: Roberto Pili
  • COMBINATION THERAPY FOR TREATING CANCER
    Publication number: 20200101081
    Abstract: The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents (such as tyrosine kinase inhibitors or VEGF/VEGFR inhibitors), particularly anticancer agents such as sunitinib, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Application
    Filed: September 6, 2019
    Publication date: April 2, 2020
    Inventors: Heike KEILHACK, Roberto PILI
  • Combination therapy for treating cancer
    Patent number: 10456407
    Abstract: The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents (such as tyrosine kinase inhibitors or VEGF/VEGFR inhibitors), particularly anticancer agents such as sunitinib, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: October 29, 2019
    Assignees: Epizyme, Inc., Health Research, Inc.
    Inventors: Heike Keilhack, Roberto Pili
  • USE OF HISTONE DEACETYLASE INHIBITORS FOR ENHANCING IMMUNOTHERAPIES
    Publication number: 20190030011
    Abstract: Compositions including combinations of class I histone deacetylase (HDAC) inhibitors and programmed cell death protein 1 (PD-1) inhibitors for enhancing antitumor activity are disclosed. Further disclosed are methods of administering these compositions as immunotherapies for suppressing regulatory T cells in renal cell carcinoma.
    Type: Application
    Filed: January 27, 2017
    Publication date: January 31, 2019
    Inventor: Roberto Pili
  • COMBINATION THERAPY FOR TREATING CANCER
    Publication number: 20180289717
    Abstract: The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents (such as tyrosine kinase inhibitors or VEGF/VEGFR inhibitors), particularly anticancer agents such as sunitinib, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Application
    Filed: April 20, 2016
    Publication date: October 11, 2018
    Inventors: Heike KEILHACK, Roberto PILI